(Total Views: 571)
Posted On: 04/08/2020 5:54:22 PM
Post# of 154119
“NYSE: 1) $5 million shareholder’s equity, 2) 18 months cash, 3) $2.00 stock price
NASDAQ: 1) $5 million shareholder’s equity, 2) 12 months cash, 3) $4.00 stock price.
They are pursuing NASDAQ.”
If the COVID indication shows efficacy in a relatively timely manner, I can see the SP over $4. If the FDA draws this out and we don’t see positive results until after the peak, I think $4 may be a little far off and we’ll have to wait until FDA approval and/or more promising cancer results.
IMO, CYDY should get a little more cash (18 months worth) and go the NYSE route as it’s quicker. Other biotechs have proven that being on a legit exchange helps bring in institutional investors and adds legitimacy to the company.
NASDAQ: 1) $5 million shareholder’s equity, 2) 12 months cash, 3) $4.00 stock price.
They are pursuing NASDAQ.”
If the COVID indication shows efficacy in a relatively timely manner, I can see the SP over $4. If the FDA draws this out and we don’t see positive results until after the peak, I think $4 may be a little far off and we’ll have to wait until FDA approval and/or more promising cancer results.
IMO, CYDY should get a little more cash (18 months worth) and go the NYSE route as it’s quicker. Other biotechs have proven that being on a legit exchange helps bring in institutional investors and adds legitimacy to the company.
(2)
(0)
